Ester Badía

Impact of an antimicrobial stewardship program indicator on the appropriateness of the empiric antibiotic treatment of urinary source Escherichia coli bacteraemia

Montserrat Giménez, Sergi Hernández, Ariadna Padullés, Lucía Boix-Palop et autres

es (code pays fourni par la source)

Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

Beatriz Muñoz, Marı́a Buti, Inmaculada Fernández, Marta Hernández Conde et autres

BACKGROUND AND AIMS: HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or …

es (code pays fourni par la source)

Autoimmune hepatitis. Another consequence of COVID-19?

Laura Andrés, Ester Badía, Cristina Fernández, Aida Puebla et autres

es (code pays fourni par la source)

Hepatitis autoinmune. ¿Otra consecuencia más de la COVID-19?

Laura Andrés, Ester Badía, Cristina Fernández, Aida Puebla et autres

es (code pays fourni par la source)

Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study

Beatriz Sicilia, Lara Arias, Gadea Hontoria, Nieves García et autres

Background: Effectiveness of corticosteroids in immunosuppressed patients with inflammatory bowel disease (IBD) has not been completely elucidated. Aims: To assess the effectiveness and examine the long-term follow-up of systemic or low-bioavailability oral steroid treatment for moderate flare-ups in patients treated with immunosuppressive …

es (code pays fourni par la source)

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

Jordi Llaneras, Mar Riveiro‐Barciela, Sabela Lens, M. Diago et autres

es (code pays fourni par la source)

Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA ‐C real‐world cohort

Marta Hernández‐Conde, Inmaculada Fernández, Christie Perelló, Adolfo Gallego et autres

In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir (EBR/GZR) demonstrated high cure rates and a good safety profile. This study assessed the effectiveness and safety of EBR/GZR, with and without ribavirin, in a real-world HCV patient cohort. HEPA-C is …

es, us (code pays fourni par la source)

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild‐moderate fibrosis: Results from a real‐world cohort

Marc Puigvehí, B. de Cuenca, Ana Viu, M. Diago et autres

BACKGROUND & AIMS: The interferon-free regimen paritaprevir/ritonavir, ombitasvir + dasabuvir (PTV/r/OBV/DSV) has shown high efficacy in patients with hepatitis C virus (HCV) genotype 1b infection when administered for 8 or 12 weeks, but data regarding the 8-week treatment are scarce. The aim …

es (code pays fourni par la source)

DISSEMINATION OF THE RESEARCH TOWARDS YOUTH: TWO ACTIVITIES OF EXPLORATORI

Dolors Grau, Imma Torra, Ester Badía, Kelly Prieto

It is well known that universities and researchers have a duty towards the society: the dissemination and exploitation of their research. The EXPLORATORI of natural resources (EXPLORATORI), a project of the Universitat Politècnica de Catalunya (UPC) aims to encourage science and technology …

Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry

Carlos Fernández‐Carrillo, Sabela Lens, Elba Llop, J.M. Pascasio et autres

Direct-acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with compensated cirrhosis. However, fewer data are available in patients with more advanced liver disease. Our retrospective, noninterventional, national, multicenter study in …

es (code pays fourni par la source)

Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting

Huascar Ramos, P. Linares, Ester Badía, I. Concepción Martín et autres

AIMTo investigated the real-world effectiveness and safety of various regimens of interferon-free treatments in patients infected with hepatitis C virus (HCV). METHODSWe performed an observational study to analyze different antiviral treatments administered to 462 HCV-infected patients, of which 56.7% had liver cirrhosis.HCV …

es (code pays fourni par la source)

Hepatitis C: Is Regression of Advanced Fibrosis Possible After Treatment?

F. Sáez-Royuela, Ester Badía

Liver cirrhosis represents a severe complication for hepatitis C patients. Patients with cirrhosis require immediate treatment; a sustained virological response has been demonstrated to reduce the probability of complications and to improve the prognosis. The optimal outcome of treatment is regression, which …

es (code pays fourni par la source)